PEDIATRIC AIDS CLINICAL TRIALS GROUP--COORDINATE/OPERATE

儿科艾滋病临床试验组——协调/操作

• 批准号: 2882223
• 负责人: STEPHEN A SPECTOR
• 金额: $ 939.56万
• 依托单位: SOCIAL AND SCIENTIFIC SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2882223
• 关键词: AIDS education /prevention; AIDS therapy; adolescence (12-20); antiAIDS agent; child (0-11); clinical research; clinical trial phase I; cooperative study; disease /disorder etiology; human pregnant subject; human subject; human therapy evaluation; opportunistic infections; pathologic process; pediatric AIDS; vertical transmission

The Pediatric AIDS Clinical Trials Group (PACTG) is the preeminent organization in the world for evaluating treatments for HlV-infected children and adolescents, and for developing new approaches for the interruption of mother-to-infant transmission. It has set the standards of care for children infected with HIV and for the interruption of vertical transmission. The PACTG is a multicenter, multidisciplinary investigative group. This cooperative agreement concerns the PACTG Coordinating and Operations Center (CORC), which includes support for the Group Leader, the Executive Committee, Other standing committees, a Community Constituency Group, the Operations Center, and the core and developmental laboratories. Associated with the CORC, under separate applications, are 18-25 pediatric AIDS Clinical Trials Units and a Statistical and Data Management Center. The Group will be managed by an Executive Committee which will oversee an integrated research agenda developed by four Research Agenda Committees (Perinatal Transmission, primary Therapy, Opportunistic Infections, and Immunology/Immune-Based Therapy (IBT)], three Scientific Committees (Virology, Immunology, and Pharmacology), and five Resource Committees (Neurology/Neuropsychology, Adolescent, Community Constituency Group, Supportive Care/Quality of Life, and Site Advisory Core Committee). The scientific agenda of the PACTG encompasses the critical issues that impact mother-to-infant transmission and treatment of HIV-infected children and adolescents. The three primary goals of the PACTG's scientific agenda are (l) to decrease mother-to-infant transmission of HIV to less than 2%, (2) to achieve a 90% 10-year survival for children perinatally infected with HIV, and (3) to develop novel strategies for early treatment of newly-infected infants and adolescents. The structure of the PACTG has been designed to provide a mechanism for a coordinated response to rapidly changing investigative opportunities for HIV-infected infants, children, adolescents, and pregnant women.

儿科艾滋病临床试验组 (PACTG) 是卓越的 世界上评估艾滋病毒感染者治疗方法的组织 儿童和青少年，并制定新的方法 阻断母婴传播。它设定了标准 照顾感染艾滋病毒的儿童和中断 垂直传输。 PACTG 是一个多中心、多学科的 调查组。该合作协议涉及 PACTG 协调和运营中心 (CORC)，包括对 组长、执行委员会、其他常务委员会、 社区选区小组、运营中心以及核心和 发展实验室。与 CORC 相关，根据单独的规定 申请，包括 18-25 个儿科艾滋病临床试验单位和一个 统计和数据管理中心。该集团将由一个 执行委员会将监督综合研究议程 由四个研究议程委员会制定（围产期传播、 主要治疗、机会性感染和免疫学/基于免疫的治疗 治疗 (IBT)]，三个科学委员会（病毒学、免疫学和 药理学）和五个资源委员会（神经病学/神经心理学， 青少年、社区选区团体、支持性护理/质量 生活和现场咨询核心委员会）。科学议程 PACTG 涵盖影响母婴的关键问题 艾滋病毒感染儿童和青少年的传播和治疗。这 PACTG 科学议程的三个主要目标是 (l) 减少 艾滋病毒母婴传播率低于 2%，(2) 实现 围产期感染 HIV 的儿童 10 年生存率为 90%，以及 (3) 制定新策略来早期治疗新感染的婴儿 和青少年。 PACTG 的结构旨在提供 对快速变化的调查做出协调反应的机制 为感染艾滋病毒的婴儿、儿童、青少年和儿童提供机会 孕妇。